Repros Therapeutics (RPRX) Reports Wider-Than-Expected Q2 Loss of $0.59; Receives Notices from FDA, Nasdaq
Tweet Send to a Friend
Repros Therapeutics (Nasdaq: RPRX) reports Q2 loss of $0.59, versus the analyst estimate of ($0.46).
The company also ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The company also ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
